Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Lower respiratory tract infection? 3,121 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 3,121 reports of Lower respiratory tract infection have been filed in association with TOFACITINIB (XELJANZ XR). This represents 2.0% of all adverse event reports for TOFACITINIB.

3,121
Reports of Lower respiratory tract infection with TOFACITINIB
2.0%
of all TOFACITINIB reports
1,127
Deaths
1,710
Hospitalizations

How Dangerous Is Lower respiratory tract infection From TOFACITINIB?

Of the 3,121 reports, 1,127 (36.1%) resulted in death, 1,710 (54.8%) required hospitalization, and 1,325 (42.5%) were considered life-threatening.

Is Lower respiratory tract infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 3,121 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Lower respiratory tract infection?

METHOTREXATE (6,049) GOLIMUMAB (5,660) ETANERCEPT (5,546) CERTOLIZUMAB PEGOL (5,137) TOCILIZUMAB (4,973) ABATACEPT (4,947) LEFLUNOMIDE (4,580) ADALIMUMAB (4,109) RITUXIMAB (4,041) ACETAMINOPHEN (3,996)

Which TOFACITINIB Alternatives Have Lower Lower respiratory tract infection Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Lower respiratory tract infection Reports All Drugs Causing Lower respiratory tract infection TOFACITINIB Demographics